Spots Global Cancer Trial Database for her3
Every month we try and update this database with for her3 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. | NCT05203601 | Tumor | SIBP-03 | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | NCT00730470 | Advanced Solid ... | U3-1287 (AMG888... | 18 Years - | U3 Pharma GmbH | |
| Assessing the Immunogenicity of pING-hHER3FL | NCT03832855 | Advanced Cancer | pING-hHER3FL | 18 Years - | Duke University | |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | NCT05785741 | Advanced Solid ... | DB-1310 | 18 Years - | DualityBio Inc. | |
| Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | NCT01966445 | Cancer Neoplasms | GSK2849330 | 18 Years - | GlaxoSmithKline | |
| HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | NCT04676477 | Non-Small Cell ... | HER3-DXd HER3-DXd Osimertinib Osimertinib HER3-DXd HER3-DXd Osimertinib | 18 Years - | Daiichi Sankyo | |
| Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors | NCT02345174 | Cancer Neoplasms | GSK2849330 89Zr-GSK2849330 | 18 Years - | GlaxoSmithKline | |
| HMBD-001 in Advanced HER3 Positive Solid Tumours | NCT05057013 | Bladder Cancer Triple Negative... Castration-resi... Cervical Cancer RAS Wild Type C... Endometrial Can... Gastric Cancer Hepatocellular ... Melanoma Non-small Cell ... Oesophageal Can... Ovarian Cancer Pancreatic Canc... Squamous Cell C... | HMBD-001 | 16 Years - | Cancer Research UK | |
| A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. | NCT05203601 | Tumor | SIBP-03 | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | NCT05919537 | Non-Small Cell ... Pancreatic Canc... Locally Advance... Metastatic Soli... | HMBD-001 Docetaxel Nab-paclitaxel Gemcitabine | 18 Years - | Hummingbird Bioscience | |
| Assessing the Immunogenicity of pING-hHER3FL | NCT03832855 | Advanced Cancer | pING-hHER3FL | 18 Years - | Duke University | |
| Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers | NCT05910827 | Advanced or Met... | HMBD-001 Docetaxel Cetuximab | 18 Years - | Hummingbird Bioscience | |
| A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. | NCT05203601 | Tumor | SIBP-03 | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | NCT01966445 | Cancer Neoplasms | GSK2849330 | 18 Years - | GlaxoSmithKline | |
| A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression | NCT04610528 | Breast Cancer | U3 1402 U3 1402 | 18 Years - | SOLTI Breast Cancer Research Group | |
| Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287) | NCT01957280 | Solid Tumors | patritumab | 18 Years - | Daiichi Sankyo | |
| A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression | NCT04610528 | Breast Cancer | U3 1402 U3 1402 | 18 Years - | SOLTI Breast Cancer Research Group | |
| Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | NCT05919537 | Non-Small Cell ... Pancreatic Canc... Locally Advance... Metastatic Soli... | HMBD-001 Docetaxel Nab-paclitaxel Gemcitabine | 18 Years - | Hummingbird Bioscience | |
| Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | NCT00730470 | Advanced Solid ... | U3-1287 (AMG888... | 18 Years - | U3 Pharma GmbH |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
